AMRI Announces Agreement with Genovi Pharmaceuticals Limited for Development and Manufacturing of Parenteral Drug Products
AMRI announced that it has entered into several development and supply agreements with Genovi Pharmaceuticals Limited to manufacture select generic parenteral drug products for registration and subsequent commercialization in the U.S., Europe, and select emerging markets.
Under the terms of the agreements, AMRI will initially provide cGMP manufacture and analytical support for the registration of five product candidates. AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches. In addition, AMRI is eligible to receive additional payments for achieving product delivery milestones. Following U.S. Food and Drug Administration approval, AMRI will supply the products to Genovi pursuant to the agreements, and for some products, receive payments based on Genovi's sales of the products. Financial details of the agreements have not been disclosed.
Other news from the department business & finance
